Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorSir Mortimer B. Davis - Jewish General Hospital

About this trial

This pilot study will evaluate the safety and 1-year erectile function recovery in 10 patients undergoing a novel Nerve Restoring Radical Cystectomy (NR-RC), which includes a genitofemoral nerve graft. Erectile function will be assessed using IIEF-5, SF-MPQ, and CEEF questionnaires at baseline and at multiple post-operative intervals (4 weeks, 3, 6, 12, and 18 months). Safety will be monitored through peri- and post-operative complications, and additional demographic and clinical data will be collected for analysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients undergoing standard of care radical cystectomy for bladder cancer

Patients must have preoperative erectile function with a baseline IIEF score of ≥17

Disqualifiers

Patients with previous pelvic surgery

Patients with previous pelvic radiotherapy

Patients aged < 18 years at diagnosis

Legally incapable patients

Trial design

Design model

Single group

Treatments tested in this trial

  • Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.

    Procedure/Surgery

    Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: Nerve Restoring Radical Cystectomy.Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Adverse events measured by the Clavian-Dindo classification

The primary outcome is specifically the safety of the operation measured by adverse events as defined by the Clavian-Dindo classification. The measurement varies from Grade I (Best possible outcome) to Grade V (Worst possible outcome). Grade I Deviation from normal p/o course. No pharmacological or surgical treatment, endoscopic or radiological interventions were required. Acceptable therapeutic drugs such as anti-emetics, antipyretics, analgesics, diuretics,electrolytes, physiotherapy. Wound infections, small abscess requiring incision at bedside. Grade II Normal course altered. Pharmacological management other than in Grade I. Blood transfusions and total parenteral nutrition are also included. Grade III Complications that require intervention of various degrees. Grade IV Complications threatening life of patients (including Central Nervous System complications), requiring Intensive Treatment Unit support. Grade V Death of a patient

Time frame
Through study completion, an average of 18 months (5 different time points)

Secondary outcomes

1

Clinical Evolution of Erectile Function (CEEF)

A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).

Time frame
4 weeks post- NR-RC
2

Clinical Evolution of Erectile Function (CEEF)

A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).

Time frame
3 months post- NR-RC
3

Clinical Evolution of Erectile Function (CEEF)

A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).

Time frame
6 months post- NR-RC
4

Clinical Evolution of Erectile Function (CEEF)

A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).

Time frame
12 months post- NR-RC

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: